Primary Open Angle Glaucoma (POAG) Market Share and Trends Analysis
DelveInsight's "Primary Open Angle Glaucoma (POAG) Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the historical and forecasted epidemiology, the pipeline insight as well as the Primary Open Angle Glaucoma (POAG) market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
The Primary Open Angle Glaucoma (POAG) market report also covers emerging drugs, current treatment practices, Primary Open Angle Glaucoma (POAG) market shares of the individual therapies, current and forecasted Primary Open Angle Glaucoma (POAG) Market Size segmented by seven major markets.
Primary Open Angle Glaucoma (POAG) Market Share and Trends Analysis
Among the 7MM, the US accounted for the largest market size of Open-Angle Glaucoma (OAG), in comparison to EU5 (United Kingdom, Spain, Italy, France, Spain) and Japan in the year 2017.
The Primary Open Angle Glaucoma (POAG) market analysis section of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Open Angle Glaucoma (POAG) market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand for better technology.
The report gives complete detail of Primary Open Angle Glaucoma (POAG) market size and shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Primary Open Angle Glaucoma (POAG) Epidemiology Forecast
The Primary Open Angle Glaucoma (POAG) epidemiology section covers insights about historical and current Primary Open Angle Glaucoma (POAG) patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
It helps to recognize the causes of current and forecasted Primary Open Angle Glaucoma (POAG) Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Treatment for Open-Angle Glaucoma (OAG) aims to lower the IOP and thus reduce the risk of progressive loss of vision, using medications, laser therapy, or conventional surgery. Treatment options for Open-Angle Glaucoma (OAG) are rapidly expanding. However, there is no cure available still.
Primary Open Angle Glaucoma (POAG) companies involved in the therapeutics development include:
Allergan
Ube Industries
Novartis
Bausch and Lomb
Nicox Ophthalmics
Ono Pharmaceutical
Alcon Research
Aerie Pharmaceuticals
Santen Pharmaceutical
Merck Sharp & Dohme Corp.
Chong Kun Dang Pharmaceutical
Sun Pharma Advanced Research Company Ltd
And many others.
Primary Open Angle Glaucoma (POAG) therapies covered in the report include:
Durysta/Bimatoprost SR
PDP–716
PRO-122
DE-130A
CKD-351
ONO-9054
NCX 470
And many more.
For more details, visit: Primary Open Angle Glaucoma (POAG) Market Share and Trends Analysis